Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 for the treatment of sickle cell disease or beta-thalassemia; and BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; BEAM-201, an anti-CD7 CAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of refractory T-cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a. The company has research collaboration agreement with Pfizer Inc., focus on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Apellis Pharmaceuticals to conduct preclinical research on target specific genes within the complement system in various organs, including the eye, liver, and brain; Verve Therapeutics, Inc., for cardiovascular disease treatments; Sana Biotechnology, Inc., to research, develop, and commercialize rights to CRISPR Cas12b for cell therapy programs; and Orbital Therapeutics design RNA for the prevention, treatment or diagnosis of human disease. Beam Therapeutics Inc. was incorporated in 2017 and is based in Cambridge, Massachusetts.
| 33.14 | |
| 32.72 | |
| - | |
| 34.09 | |
| 32.35 | |
| 16.95-49.5 | |
| 2 648 M | |
| 82 311 K | |
| 361 M | |
| -1.21 | |
| 1.871 |
No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.
One important metric to look for in a stock is an 80 or higher Relative Strength Rating. Beam Therapeutics stock now clears that threshold, with a jump from 65 to 85 Wednesday. IBD's proprietary rating tracks market leadership with a 1 (worst) to 99 (best) score. Continue reading View comments
CRISPR Therapeutics (CRSP) stock has been pushing downwards in recent weeks, taking it near a 52-week low. The stock’s fall likely reflects the broader selloff and rotation away from technology stoc...
Our 24/7 support would be happy to assist you via chat or email:
support@eodhistoricaldata.comVisit also:
